An Indian biotech company aims to restore vision

Share via:


Ever thought an Indian company could be developing a drug that restores vision? That could soon be the case with Eyestem Research, a Bengaluru- and US-based biotech company working on cell therapy for retinal diseases. Its lead program, Eyecyte-RPE, is designed to treat Geographic Atrophy—the advanced stage of dry age-related macular degeneration (AMD), a leading cause of blindness in people over 50. Globally, around 19.6 crore people live with AMD, of which nearly 50 lakh suffer from GA.

Continue Reading with
CNBC-TV18 Access Membership

Priority…



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Popular

More Like this

An Indian biotech company aims to restore vision


Ever thought an Indian company could be developing a drug that restores vision? That could soon be the case with Eyestem Research, a Bengaluru- and US-based biotech company working on cell therapy for retinal diseases. Its lead program, Eyecyte-RPE, is designed to treat Geographic Atrophy—the advanced stage of dry age-related macular degeneration (AMD), a leading cause of blindness in people over 50. Globally, around 19.6 crore people live with AMD, of which nearly 50 lakh suffer from GA.

Continue Reading with
CNBC-TV18 Access Membership

Priority…



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Website Upgradation is going on for any glitch kindly connect at office@startupnews.fyi

More like this

Apple settles Brazilian antitrust case with App Store policy...

Starting next year, Apple will allow app sideloading...

Quick Commerce In 2026, Layoffs At Yellow.ai & More

What Lies Ahead For Quick Commerce?  As 2025 draws...

5 smartwatches that I am adding to my New...

The start of a new year feels like...

Popular